<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175395</url>
  </required_header>
  <id_info>
    <org_study_id>2009-1067</org_study_id>
    <nct_id>NCT01175395</nct_id>
  </id_info>
  <brief_title>20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)</brief_title>
  <acronym>20089/Combo</acronym>
  <official_title>An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With LucentisÂ® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Bioscience Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety &amp; tolerability of an
      investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg
      in subjects with sub-foveal neovascular AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is being done to test the safety and effectiveness of an investigational drug 20089
      TA that will be used in combination with Lucentis for the treatment of CNVM. In CNVM, tiny
      abnormal blood vessels grow through the retinal layers in the eye. These vessels are very
      fragile and can leak or bleed. The severity of the symptoms depends on the size of the CNVM
      and its proximity to the macula (the center of visual field). Symptoms may be mild such as a
      blurry or distorted area of vision, or more severe, like a central blind spot. Although
      Lucentis has been approved by the U.S. Food and Drug Administration (FDA) for the treatment
      of CNVM, the study drug 20089 TA has not yet been approved, and therefore is considered an
      investigational drug.

      Triamcinolone Acetonide (TA) is a corticosteroid (an anti-inflammatory drug) that is used to
      treat many eye diseases, such as: macular edema (where inflammation causes thickening of the
      macula), diabetic eye disease, and age-related macular degeneration. TA has also been shown
      to be effective in treating neovascular AMD (also known as &quot;wet AMD&quot;) where there is an
      abnormal growth of blood vessels in the macula.

      Study drug 20089 is an experimental form of the corticosteroid, Triamcinolone Acetonide(TA).
      20089 is a new slow-release formula (longer lasting) for intravitreal (into the eye) delivery
      of TA. This drug releases the active agent TA over a period of approximately 6 months thereby
      allowing for the improvement of inflammation and/or complications following neovascular AMD.

      Although intravitreal Lucentis has been shown to prevent the loss of vision in most
      neovascular AMD patients and help gain visual acuity (how well we can see), results can only
      be assured if monthly injections are given. Since monthly injections are a burden on the
      patient and caregiver, attempts are being made to reduce the burden by combining available
      treatment options. We hope that by combining 20089 TA with Lucentis a decrease in retinal
      inflammation, closure of the leaky vessels with a decrease in the number of monthly
      injections could be achieved.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Assess the Safety &amp; Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD</measure>
    <time_frame>360 Days</time_frame>
    <description>The primary objective is to assess the ocular safety of 20089 TA (6.9 mg or 13.8 mg)treatment in combination with Lucentis.
The ocular safety endpoints to be assessed include the number of participants with ocular Adverse Events such as: evidence of endophthalmitis, uveitis, ocular hemorrhage, retinal tear or detachment to be assessed during ophthalmic examinations. Elevated IOP as measured by an applanation tonometer at every visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Number of Retreatments With Lucentis in Eyes Initially Treated With 20089 TA and Lucentis</measure>
    <time_frame>30 to 360 days</time_frame>
    <description>Because of the combination - 20089/Lucentis - treatment, patients may not require monthly Lucentis injections as is the current standard of care practice for AMD.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>IBI-20089/Lucentis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI-20089/Lucentis</intervention_name>
    <description>Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.</description>
    <arm_group_label>IBI-20089/Lucentis</arm_group_label>
    <other_name>IBI-20089 (Triamcinolone Acetonide)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female subjects, 55 years of age and older.

          2. Diagnosis of active, subfoveal choroidal neovascular membranes (CNVM) due to age
             related macular degeneration (AMD)

          3. Visual acuity from 20/25 to 20/400 in the study eye.

        Exclusion Criteria:

          1. Subjects who have received corticosteroids via any route in the past 30 days.

          2. In the opinion of the investigator, patient is known to be a steroid-responder.

          3. Subjects with a history of uncontrolled glaucoma (Primary or Secondary)

          4. History of ocular surgery (invasive or non-invasive) in the past 90 days

          5. Intravitreal treatment with an anti-VEGF agent e.g. bevacizumab, ranibizumab, or
             pegaptanib within 30 days of the enrollment (Day 0) examination.

          6. Patients requiring systemic steroids (greater than 15 mg daily by mouth) or systemic
             immunomodulatory agents.

          7. Active ocular or periocular infection (i.e., bacterial, viral, parasitic or fungal) in
             either eye or a history of herpetic ocular infection in either eye.

          8. Media opacity in the study eye precluding observation or photography of the fundus.

          9. Any other clinically significant medical or psychological condition that, in the
             opinion of the Investigator, would jeopardize the safety of the patient or affect the
             validity of the study results.

         10. Participation in a clinical trial of an investigational drug or device within 30 days
             of the screening visit.

         11. Known history of allergy to corticosteroids.

         12. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer I Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UIC Eye and Ear Infirmary</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uic.edu/com/eye/</url>
    <description>UIC-Ophthalmology Home Page</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <results_first_submitted>May 23, 2013</results_first_submitted>
  <results_first_submitted_qc>October 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2014</results_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Jennifer I. Lim</investigator_full_name>
    <investigator_title>Professor of Ophthalmology, Director of Retina Services, Department of Ophthalmology and Visual Sciences</investigator_title>
  </responsible_party>
  <keyword>Choroidal neovascular membranes</keyword>
  <keyword>CNV</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-relate Macular Degeneration</keyword>
  <keyword>CNVM</keyword>
  <keyword>subfoveal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from Sept 2010 to January 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IBI-20089/Lucentis</title>
          <description>Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
IBI-20089/Lucentis : Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IBI-20089/Lucentis</title>
          <description>Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
IBI-20089/Lucentis : Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Safety &amp; Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD</title>
        <description>The primary objective is to assess the ocular safety of 20089 TA (6.9 mg or 13.8 mg)treatment in combination with Lucentis.
The ocular safety endpoints to be assessed include the number of participants with ocular Adverse Events such as: evidence of endophthalmitis, uveitis, ocular hemorrhage, retinal tear or detachment to be assessed during ophthalmic examinations. Elevated IOP as measured by an applanation tonometer at every visit.</description>
        <time_frame>360 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IBI-20089/Lucentis</title>
            <description>Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
IBI-20089/Lucentis : Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Safety &amp; Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD</title>
          <description>The primary objective is to assess the ocular safety of 20089 TA (6.9 mg or 13.8 mg)treatment in combination with Lucentis.
The ocular safety endpoints to be assessed include the number of participants with ocular Adverse Events such as: evidence of endophthalmitis, uveitis, ocular hemorrhage, retinal tear or detachment to be assessed during ophthalmic examinations. Elevated IOP as measured by an applanation tonometer at every visit.</description>
          <units>Number-participants with adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Number of Retreatments With Lucentis in Eyes Initially Treated With 20089 TA and Lucentis</title>
        <description>Because of the combination - 20089/Lucentis - treatment, patients may not require monthly Lucentis injections as is the current standard of care practice for AMD.</description>
        <time_frame>30 to 360 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IBI-20089/Lucentis</title>
            <description>Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
IBI-20089/Lucentis : Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Number of Retreatments With Lucentis in Eyes Initially Treated With 20089 TA and Lucentis</title>
          <description>Because of the combination - 20089/Lucentis - treatment, patients may not require monthly Lucentis injections as is the current standard of care practice for AMD.</description>
          <units>retreatments</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Number of subjects who developed progression of cataract Number of subjects with intraocular pressure (IOP) elevation above 25 mmHg Number of subjects with any severe ocular adverse event Number of subjects with any severe systemic adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>IBI-20089/Lucentis</title>
          <description>Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
IBI-20089/Lucentis : Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture of sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>subconjunctival hemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>cataract surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>vitreous floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>temporal pallor of optic nerve</sub_title>
                <description>Secondary and due to retinal atrophy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>posterior vitreous detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>retinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ptosis of eyelid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>watery eye</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>food poisoning</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>infective vaginitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to eye condition or treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer I Lim MD</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>312-413-0704</phone>
      <email>jennylim@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

